October 9, 2020 11:46 AM EDTUpdated October 9, 10:48 PM
Discovery

Park­er In­sti­tute sum­moned the neoanti­gen pi­o­neers to com­pare their pre­dic­tion al­go­rithms. And they have some sug­ges­tions for the field

Amber Tong

What makes a good neoanti­gen?

For all the promis­es of the bold new ap­proach to can­cer vac­cines and ther­a­pies — ze­ro­ing in on spe­cif­ic mu­tat­ed anti­gens …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Up­dat­ed: Pfiz­er's ac­tivist says board must 'hold man­age­ment ac­count­able' for R&D short­com­ings

Ahead of No­vo’s Ca­griSe­ma read­out, Lil­ly re­turns to a promis­ing new class of obe­si­ty drugs

Roche, Genen­tech end an­ti-tau Alzheimer’s drug col­lab­o­ra­tion with UCB

Ed­i­tas piv­ots away from ex vi­vo sick­le cell ther­a­py in fa­vor of in vi­vo ap­proach

Ot­su­ka’s cy­tokine-tar­get­ing drug for IgAN clears Phase 3 hur­dle

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times